Expression and prognostic value of miR-486- 5p in patients with gastric adenocarcinoma 5p in patients with gastric adenocarcinoma

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Chen, Hui ^a   Ren, Chuanli ^a,b   Han, Chongxu ^a   Wang, Daxin ^a   Chen, Yong ^a   Fu, Deyuan ^a  

^a CLINICAL MEDICAL COLLEGE OF YANGZHOU UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 9; LOCKED NUCLEIC ACID; MICRORNA; PROTEIN MIR 486 5P; UNCLASSIFIED DRUG; MESSENGER RNA; MIRN486 MICRORNA, HUMAN;

ADULT; ARTICLE; BIOINFORMATICS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; RADICAL RESECTION; STOMACH ADENOCARCINOMA; TISSUE MICROARRAY; TUMOR INVASION; TUMOR VOLUME; ADENOCARCINOMA; AGED; FOLLOW UP; GENE EXPRESSION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RNA INTERFERENCE; STOMACH TUMOR; SURVIVAL ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; FEMALE; FIBROBLAST GROWTH FACTOR 9; FOLLOW-UP STUDIES; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RNA INTERFERENCE; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR BURDEN;

EID: 84925660130     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119384     Document Type: Article

References (35)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010 Dec 15; 127(12).
2. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet 2009 Aug 8; 374 (9688).
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004 Jan 23; 116(2).
4. van Kouwenhove M, Kedde M, Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer 2011 Aug 5; 11(9). doi: 10.1038/nrc3004-c1 PMID: 21863051
5. Villarroya-Beltri C, Gutierrez-Vazquez C, Sanchez-Cabo F, Perez-Hernandez D, Vazquez J, Martin- Cofreces N, et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat Commun 2013; 4.
6. Shen J, Liu Z, Todd NW, Zhang H, Liao J, Yu L, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 2011 Aug 24; 11.
7. Tan X, Qin W, Zhang L, Hang J, Li B, Zhang C, et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res 2011 Nov 1; 17(21).
8. Navon R, Wang H, Steinfeld I, Tsalenko A, Ben-Dor A, Yakhini Z. Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One 2009 Nov 25; 4(11). doi: 10.1371/journal.pone.0008003 PMID: 19946373
9. Bansal A, Lee IH, Hong X, Anand V, Mathur SC, Gaddam S, et al. Feasibility of mcroRNAs as biomarkers for Barrett's Esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am J Gastroenterol2011Jun; 106(6).
10. Ragusa M, Majorana A, Statello L, Maugeri M, Salito L, Barbagallo D, et al. Specific alterations of micro- RNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther 2010 Dec; 9(12).
11. Oh HK, Tan AL, Das K, Ooi CH, Deng NT, Tan IB, et al. Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clin Cancer Res 2011 May 1; 17(9).
12. Peng Y, Dai Y, Hitchcock C, Yang X, Kassis ES, Liu L, et al. Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer. Proc Natl Acad Sci U S A 2013 Sep 10; 110(37).
13. Tahiri A, Leivonen SK, Luders T, Steinfeld I, Ragle Aure M, Geisler J, et al. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis 2013; 35(1).
14. Goto K, Oue N, Shinmei S, Sentani K, Sakamoto N, Naito Y, et al. Expression of is a potential prognostic factor after nephrectomy in advanced renal cell carcinoma. Mol Clin Oncol 2013 Jan;; 1(2).
15. Zhu C, Ren C, Han J, Ding Y, Du J, Dai N, et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer 2014 Apr 29; 110(9).
16. Konishi H, Ichikawa D, Komatsu S, Shiozaki A, Tsujiura M, Takeshita H, et al. Detection of gastric can-cer- associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. Br J Cancer 2012; 106(4).
17. Wang J, Tian X, Han R, Zhang X, Wang X, Shen H, et al. Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene 2014 Feb 14; 33(9). doi: 10.1038/onc.2013.69 PMID: 23542179
18. Li Y, Liang L, Zhang CY. Isothermally sensitive detection of serum circulating miRNAs for lung cancer diagnosis. Anal Chem 2013 Dec 3; 85(23).
19. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10(2). doi: 10.1038/nrc2627-c1 PMID: 20094050
20. He C, Jiang H, Geng S, Sheng H, Shen X, Zhang X, et al. Expression and prognostic value of c-Myc and Fas (CD95/APO1) in patients with pancreatic cancer. Int J Clin Exp Pathol 2014 Feb; 7(2).
21. Zhang CZ, Zhang JX, Zhang AL, Shi ZD, Han L, Jia ZF, et al. MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer 2010 Sep 2; 9.
22. Teishima J, Shoji K, Hayashi T, Miyamoto K, Ohara S, Matsubara A. Relationship between the localization of fibroblast growth factor 9 in prostate cancer cells and postoperative recurrence. Prostate Cancer Prostatic Dis 2012 Mar; 15(1). doi: 10.1038/pcan.2011.53 PMID: 22249290
23. Kim YJ, Hwang SH, Lee SY, Shin KK, Cho HH, Bae YC, et al. miR-486-5p induces replicative senescence of human adipose tissue-derived mesenchymal stem cells and its expression is controlled by high glucose. Stem Cells Dev 2012 Jul 1; 21(10).
24. Zhang G, Liu Z, Cui G, Wang X, Yang Z. MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells. Tumour Biol 2014 Nov; 35(11).
25. Alexander MS, Casar JC, Motohashi N, Vieira NM, Eisenberg I, Marshall JL, et al. MicroRNA-486- dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptoms. J Clin Invest 2014 Jun 2; 124(6).
26. Small EM O'Rourke JR, Moresi V, Sutherland LB, McAnally J, Gerard RD, et al. Regulation of PI3-kinase/ Akt signaling by muscle-enriched microRNA-486. Proc Natl Acad Sci U S A 2010 Mar 2; 107(9).
27. Mees ST, Mardin WA, Sielker S, Willscher E, Senninger N, Schleicher C, et al. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol 2009 Aug; 16(8).
28. Stuelten CH, Salomon DS. miR-31 in cancer: location matters. Cell Cycle 2010 Dec 1; 9(23).
29. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, et al. Serum microRNA signatures identified in a genomewide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010 Apr 1; 28(10).
30. Xie Z, Chen G, Zhang X, Li D, Huang J, Yang C, et al. Salivary microRNAs as promising biomarkers for detection of esophageal cancer. PLoS One 2013 Apr 1; 8(4).
31. Ohgino K, Soejima K, Yasuda H, Hayashi Y, Hamamoto J, Naoki K, et al. Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer. Lung Cancer 2014 Jan; 83(1). doi: 10.1016/j.lungcan.2013.11.002 PMID: 24290256
32. Deng M, Tang HL, Lu XH, Liu MY, Lu XM, Gu YX, et al. miR-26a Suppresses Tumor Growth and Metastasis by Targeting FGF9 in Gastric Cancer. PLoS One 2013 Aug 28; 8(8).
33. Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 2010 Dec 15; 127(12).
34. Rask L, Balslev E, Sokilde R, Hogdall E, Flyger H, Eriksen J, et al. Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status. Cell Oncol (Dordr) 2014 Jun; 37(3).
35. Wu ZB, Li WQ, Lin SJ, Wang CD, Cai L, Lu JL, et al. MicroRNA expression profile of bromocriptine-resistant prolactinomas. Mol Cell Endocrinol 2014 Sep; 395(1-2). doi: 10.1016/j.mce.2014.07.018 PMID: 25109277